Catherine Kim1, Vanita R Aroda2, Ronald B Goldberg3, Naji Younes4, Sharon L Edelstein4, MaryLou Carrion-Petersen5, David A Ehrmann6. 1. Departments of Medicine, Obstetrics & Gynecology, and Epidemiology, University of Michigan, Ann Arbor, Michigan. 2. MedStar Health Research Institute, Hyattsville, Maryland. 3. Department of Medicine, University of Miami, Miami, Florida. 4. Biostatistics Center, George Washington University, Rockville, Maryland. 5. Department of Family and Preventive Medicine, University of California, San Diego, California. 6. Department of Medicine, University of Chicago, Chicago, Illinois.
Abstract
Context: It is unclear whether relative elevations in androgens or irregular menses (IM) are associated with greater cardiometabolic risk among women who are already overweight and glucose intolerant. Research Design and Methods: We conducted a secondary analysis of the Diabetes Prevention Program (DPP) and the Diabetes Prevention Program Outcomes Study (DPPOS). Participants included women with sex hormone measurements who did not use exogenous estrogen (n = 1422). We examined whether free androgen index (FAI) or IM was associated with diabetes risk during the DPP/DPPOS or with coronary artery calcification (CAC) at DPPOS year 10. Models were adjusted for menopausal status, age, race or ethnicity, randomization arm, body mass index (BMI), and hemoglobin A1c. Results: Women had an average age of 48.2 ± 9.9 years. Elevations in FAI and IM were associated with greater BMI, waist circumference, and blood pressure and lower adiponectin. FAI was not associated with diabetes risk during the DPP/DPPOS [hazard ratio (HR) 0.97; 95% confidence interval (CI), 0.93 to 1.02] or increased odds of CAC [odds ratio (OR) 1.06; 95% CI, 0.92 to 1.23]. IM was also not associated with diabetes risk during the DPP/DPPOS (HR 1.07; 95% CI, 0.87 to 1.31) or increased odds of CAC (OR 0.89; 95% CI, 0.53 to 1.49). Women who had both relative elevations in FAI and IM had similar diabetes risk and odds of CAC as women without these conditions. Differences by treatment arm and menopausal status were not observed. Conclusions: Among midlife women who were already glucose intolerant and overweight, androgen concentrations and IM did not additionally contribute to increased risk for diabetes or CAC.
RCT Entities:
Context: It is unclear whether relative elevations in androgens or irregular menses (IM) are associated with greater cardiometabolic risk among women who are already overweight and glucose intolerant. Research Design and Methods: We conducted a secondary analysis of the Diabetes Prevention Program (DPP) and the Diabetes Prevention Program Outcomes Study (DPPOS). Participants included women with sex hormone measurements who did not use exogenous estrogen (n = 1422). We examined whether free androgen index (FAI) or IM was associated with diabetes risk during the DPP/DPPOS or with coronary artery calcification (CAC) at DPPOS year 10. Models were adjusted for menopausal status, age, race or ethnicity, randomization arm, body mass index (BMI), and hemoglobin A1c. Results:Women had an average age of 48.2 ± 9.9 years. Elevations in FAI and IM were associated with greater BMI, waist circumference, and blood pressure and lower adiponectin. FAI was not associated with diabetes risk during the DPP/DPPOS [hazard ratio (HR) 0.97; 95% confidence interval (CI), 0.93 to 1.02] or increased odds of CAC [odds ratio (OR) 1.06; 95% CI, 0.92 to 1.23]. IM was also not associated with diabetes risk during the DPP/DPPOS (HR 1.07; 95% CI, 0.87 to 1.31) or increased odds of CAC (OR 0.89; 95% CI, 0.53 to 1.49). Women who had both relative elevations in FAI and IM had similar diabetes risk and odds of CAC as women without these conditions. Differences by treatment arm and menopausal status were not observed. Conclusions: Among midlife women who were already glucose intolerant and overweight, androgen concentrations and IM did not additionally contribute to increased risk for diabetes or CAC.
Authors: Sherita Hill Golden; Ann Maguire; Jingzhong Ding; J R Crouse; Jane A Cauley; Howard Zacur; Moyses Szklo Journal: Am J Epidemiol Date: 2002-03-01 Impact factor: 4.897
Authors: Joachim Spranger; Matthias Möhlig; Uta Wegewitz; Michael Ristow; Andreas F H Pfeiffer; Thilo Schill; Hans W Schlösser; Georg Brabant; Christof Schöfl Journal: Clin Endocrinol (Oxf) Date: 2004-12 Impact factor: 3.478
Authors: Theodore P Ciaraldi; Vanita Aroda; Sunder Mudaliar; R Jeffrey Chang; Robert R Henry Journal: J Clin Endocrinol Metab Date: 2008-10-14 Impact factor: 5.958
Authors: Benjamin Fenske; Hanna Kische; Stefan Gross; Henri Wallaschofski; Henry Völzke; Marcus Dörr; Matthias Nauck; Brian G Keevil; Georg Brabant; Robin Haring Journal: J Clin Endocrinol Metab Date: 2015-10-07 Impact factor: 5.958
Authors: E M Venditti; G A Bray; M L Carrion-Petersen; L M Delahanty; S L Edelstein; R F Hamman; M A Hoskin; W C Knowler; Y Ma Journal: Int J Obes (Lond) Date: 2008-08-19 Impact factor: 5.095
Authors: Ronit Calderon-Margalit; David Siscovick; Sharon S Merkin; Erica Wang; Martha L Daviglus; Pamela J Schreiner; Barbara Sternfeld; O Dale Williams; Cora E Lewis; Ricardo Azziz; Stephen M Schwartz; Melissa F Wellons Journal: Arterioscler Thromb Vasc Biol Date: 2014-10-30 Impact factor: 8.311
Authors: Juan José Hidalgo-Mora; Laura Cortés-Sierra; Miguel-Ángel García-Pérez; Juan J Tarín; Antonio Cano Journal: Nutrients Date: 2020-10-18 Impact factor: 5.717